Bradley Merrill Thompson

News
Motor vehicles stalled in a traffic jam
Commentary: Digital health companies should stay away from FDA in 2021
By Bradley Merrill Thompson 05:20 pm December 23, 2020
As the agency's workload swells with the weight of a public health emergency, digital health companies on a timeline should consider whether their products truly warrant a regulatory submission, writes Epstein Becker & Green's Bradley Merrill Thompson.

The Daily Brief Newsletter

Get daily news updates from Healthcare IT News.
Your subscription has been saved.
Something went wrong. Please try again.

More Stories

Marjorie Rosen at HIMSS_Global Health Equity Week 2024
HIMSS chapters offer a powerful channel for healthcare advocacy
Returning service member with daughter
HIMSS launches veterans health IT workforce program
Morgan L. Waller, RN, of Children's Mercy Kansas City on telemedicine
Deep dive: Exploring one of the most advanced telemedicine programs in the U.S.
Person on laptop at kitchen table with another who holds up prescription bottle for telehealth doctor
ATA calls on Congress to beat the telehealth deadline, as it preps for Trump's term
Anurag Mehta at Omega Healthcare_Physician working on laptop Photo by Dzonsli/E+/Getty Images
Clinician burnout can be reduced by virtual nursing
Healthcare worker and patient watching doctor on screen
Discover the potential ROI of bedside telehealth
HKUST Provost professor Guo Yike presenting their new health LLMs
Hong Kong university to test four genAI models in...
A doctor in a virtual consultation with a patient
China to pilot standards for virtual primary care